母亲抗钠钾泵α1亚基(AT1A1)自身抗体与胎儿自身免疫性先天性心脏传导阻滞:病例对照研究
该病例对照研究分析两个中心受自身免疫性先天性心脏传导阻滞影响与未受影响妊娠的母亲血样,发现受影响妊娠存在针对胎儿心脏蛋白的自身抗体谱扩展,其中抗AT1A1自身抗体在三个队列的全部受影响妊娠中均检出,而在无心脏传导阻滞史且未受影响妊娠中大多缺失,提示其可能作为早期预测生物标志物。
要点
- 抗AT1A1自身抗体在发现队列6/6、验证队列22/22、验证队列16/16受影响妊娠中均检出。
- 无胎儿心脏传导阻滞史且未受影响妊娠中抗AT1A1自身抗体缺失者为54/65(83%)。
- 抗AT1A1自身抗体最早在妊娠7周即可检出,且早于心脏传导阻滞发生。
核心结论
- 研究识别出一种靶向胎儿AT1A1心脏蛋白的新型母体自身抗体,可能作为既往无受累妊娠的孕妇早期准确检测胎儿自身免疫性先天性心脏传导阻滞的潜在生物标志物。
- 该进展可能通过增强监测和及时、知情的治疗干预改善高危妊娠的母胎管理。
研究设计与样本
- 病例对照研究,分析来自两个中心(加拿大病童医院和意大利帕多瓦大学)受与未受自身免疫性先天性心脏传导阻滞影响妊娠的母亲血样。
- 关键纳入标准为母亲抗干燥综合征相关抗原A/Ro自身抗体临床检测阳性,关键排除标准为与心脏传导阻滞相关的结构性先天性心脏病。
- 病例为导致胎儿或新生儿先天性心脏传导阻滞的妊娠,对照为导致后代心律正常的妊娠。
- 发现队列血清采集于2010年1月1日至2020年12月31日(病童医院),验证队列采集于1999年8月1日至2019年12月31日(帕多瓦大学医院),确认队列采集于2018年6月1日至2023年8月31日(病童医院)。
- 发现队列母亲平均年龄34.2岁(SD 5.2),验证队列33.5岁(4.6),确认队列32.8岁(4.3)。
主要发现
- 受胎儿自身免疫性先天性心脏传导阻滞影响的妊娠(病例;n=46)母亲血清显示抗心脏自身抗体谱较未受影响妊娠(对照;n=65)扩展。
- 质谱鉴定出11种母体自身抗体的潜在心脏蛋白靶点,受影响妊娠血清样本中确认了7种自身抗体的存在。
- 四种靶点(ANXA1、BIP、MYPC3和AT1A1)在先天性心脏传导阻滞发生前即被鉴定。
- 抗Na+和K+ ATP酶α1亚型(AT1A1)的母体自身抗体最早在妊娠7周检出,且在无论有无既往胎儿心脏传导阻滞史的母亲的全部受影响妊娠中均存在(发现队列6/6[100%],验证队列22/22[100%],确认队列16/16[100%])。
- 无胎儿心脏传导阻滞史的孕妇中,所有未受影响妊娠均缺失抗AT1A1自身抗体(54/65[83%])。
关键数值与推荐
- 抗AT1A1自身抗体在发现队列受影响妊娠中检出率为6/6(100%),验证队列为22/22(100%),确认队列为16/16(100%)。
- 无胎儿心脏传导阻滞史且未受影响妊娠中抗AT1A1自身抗体缺失比例为54/65(83%)。
- 使用受试者工作特征曲线评估预测胎儿心脏传导阻滞结局的敏感性和特异性。
临床怎么用
- 原文结论指出,抗AT1A1自身抗体可能作为既往无受累妊娠的孕妇早期准确检测胎儿自身免疫性先天性心脏传导阻滞的潜在生物标志物。
- 原文结论指出,该进展可能通过增强监测和及时、知情的治疗干预改善高危妊娠的母胎管理。
局限性
- 本研究在设计或实施中未纳入有亲身经历的个人。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fetal autoimmune congenital heart block is a rare but life-threatening condition that is difficult to predict. This study sought to identify a serological biomarker predictive of autoimmune congenital heart block in pregnancies at risk due to maternal systemic lupus erythematosus, Sjögren's disease, undifferentiated connective tissue disease, or a history of congenital heart block offspring. METHODS: This case-control study analysed maternal blood samples from pregnancies affected and unaffected by autoimmune congenital heart block from two centres (The Hospital for Sick Children, Canada, and The University of Padua, Italy). Serum samples collected across varying gestational ages were used for biomarker discovery, verification, and validation. The key inclusion criterion was a positive clinical test for maternal anti-Sjögren's syndrome-related antigen A/Ro autoantibodies, and the key exclusion criterion was structural congenital heart disease associated with heart block. Cases were pregnancies that resulted in fetal or neonatal congenital heart block and controls were pregnancies that resulted in offspring with a normal heart rhythm. Two-dimensional western blotting was used to identify maternal autoantibodies targeting fetal cardiac proteins, using fetal heart tissue and stem-cell-derived cardiomyocytes. Findings were validated using commercial proteins. Sensitivity and specificity for predicting fetal heart block outcomes were assessed using receiver-operating characteristic curves. The primary study outcomes were the presence and specificity of anti-cardiac autoantibodies in autoimmune congenital heart block cases versus controls, the association between specific autoantibodies and congenital heart block development, and the predictive accuracy of identified autoantibodies. This study did not involve individuals with lived experience in the study design or implementation. FINDINGS: Serum samples were collected between Jan 1, 2010, and Dec 31, 2020, in the discovery cohort (The Hospital for Sick Children), between Aug 1, 1999, and Dec 31, 2019 in the verification cohort (University Hospital of Padua), and between June 1, 2018, and Aug 31, 2023, in the validation cohort (The Hospital for Sick Children). Mean maternal age was 34·2 years (SD 5·2) in the discovery cohort, 33·5 years (4·6) in the verification cohort, and 32·8 years (4·3) in the validation cohort. Maternal serum samples from pregnancies affected by fetal autoimmune congenital heart block (cases; n=46) showed an expanded repertoire of anti-cardiac autoantibodies compared with unaffected pregnancies (controls; n=65). Mass spectrometry identified 11 potential cardiac protein targets for maternal autoantibodies and the presence of seven autoantibodies were confirmed in serum samples from affected pregnancies. Four targets were identified before the onset of congenital heart block (ANXA1, BIP, MYPC3, and AT1A1). Maternal autoantibodies against the Na+ and K+ ATPase α1 isoform (AT1A1) were detected as early as 7 weeks gestation and were present in all affected pregnancies of mothers with and without previous fetal heart block history (six [100%] of six in the discovery cohort, 22 [100%] of 22 in the verification cohort, and 16 [100%] of 16 in the validation cohort). Anti-AT1A1 autoantibodies were absent in all unaffected pregnancies in pregnant women with no fetal heart block history (54/65 [83%]). INTERPRETATION: This study identifies a novel maternal autoantibody targeting the fetal AT1A1 cardiac protein as a potential biomarker for the early and accurate detection of fetal autoimmune congenital heart block in pregnant women who had not previously had an affected pregnancy. This advancement might improve the maternal-fetal management of at-risk pregnancies through enhanced surveillance and timely and informed therapeutic interventions. FUNDING: Heart and Stroke Foundation of Canada and Canadian Institutes of Health Research.
引用
- Benjamin S, Vi L, Chatterjee D, et al. Maternal autoantibodies to the sodium potassium pump α1 subunit AT1A1 and fetal autoimmune congenital heart block: a case-control study. Lancet Rheumatol. 2025. PMID: 40412415. doi:10.1016/S2665-9913(25)00092-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。